NSRX
Nasus Pharma Ltd. (NSRX) Risks & Opportunities Analysis (2026)
No material changes this month.
Risks
Leverage appears modest versus many small-cap peers, but zero interest coverage and limited disclosed earnings visibility raise refinancing sensitivity if operating cash flow weakens.
Liquidity is strong with a current ratio near 8.8, yet peers with steadier profitability can convert balance-sheet strength into lower funding risk more reliably.
The absence of reported efficiency metrics and FCF margin limits evidence of cash-generation durability, which can weigh on valuation versus better-disclosed peers.
Net debt to EBITDA around 1.1 suggests manageable leverage, but peers with net-cash or lower-debt profiles retain more flexibility in a tighter capital market.
Opportunities
High current and quick ratios provide near-term balance-sheet flexibility, supporting execution versus more levered peers if working capital or growth investment needs rise.
Net debt to EBITDA near 1.1 leaves room for incremental operating improvement to translate into faster deleveraging than peers with heavier balance-sheet burdens.
If cash generation normalizes, the combination of low debt-to-equity and strong liquidity could improve financing terms relative to similarly sized competitors.
Limited leverage can preserve strategic optionality in a volatile funding environment, giving NSRX more resilience than peers that must prioritize debt service.
Overall Score
NSRX shows balance-sheet resilience and moderate leverage, but weak visibility on cash generation and zero interest coverage keep peer-relative positioning only moderately attractive.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Nasus Pharma Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
